Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

The black-box warning on Pfizer’s smoking-cessation drug Chantix (varenicline) just got bigger, following the results of a new study that found the drug caused an increased risk of heart attack and other adverse cardiac events in some patients. According to the U.S. Food and Drug Administration, the warning on Chantix labeling will include information about the safety and effectiveness of the drug in patients with existing cardiovascular disease and those with chronic obstructive pulmonary disease (COPD).

Read the rest of this entry »

Last month, the Food and Drug Administration warned of newly discovered cardiovascular risks associated with Pfizer’s popular smoking-cessation drug Chantix. But it turns out those risks, which include higher occurrence of heart attack and other adverse cardiovascular events in Chantix users with heart disease, pale in comparison to the findings of a larger study that found many of the same risks exist in Chantix patients with no heart disease.

Read the rest of this entry »

For many smokers trying to kick their addiction, the latest news about the dangers of Pfizer’s smoking-cessation drug Chantix presents as a damned if you do, damned if you don’t dilemma. The U.S. Food and Drug Administration issued an alert yesterday, warning that use of the popular drug could lead to increased risk of heart attack and other adverse cardiovascular events.

Read the rest of this entry »

A senior scientist working for the non-profit Institute for Safe Medicine Practices has discovered that Chantix is a much more dangerous drug than has been officially acknowledged after finding hundreds of serious adverse reactions were reported to the FDA by manufacturer Pfizer Inc. through improper channels.

Read the rest of this entry »